Increased bacterial taxonomic and functional diversity is associated with impaired rotavirus vaccine immunogenicity in infants from India and Malawi.


Journal

BMC microbiology
ISSN: 1471-2180
Titre abrégé: BMC Microbiol
Pays: England
ID NLM: 100966981

Informations de publication

Date de publication:
18 11 2023
Historique:
received: 05 06 2023
accepted: 30 10 2023
medline: 20 11 2023
pubmed: 19 11 2023
entrez: 19 11 2023
Statut: epublish

Résumé

The immunogenicity and effectiveness of oral rotavirus vaccines (ORVs) against severe rotavirus-associated gastroenteritis are impaired in low- and middle-income countries (LMICs) where the burden of disease is highest. Determining risk factors for impaired ORV response may help identify strategies to enhance vaccine effectiveness. In this study, we use metagenomic sequencing to provide a high-resolution taxonomic analysis of stool samples collected at 6 weeks of age (coinciding with the first ORV dose) during a prospective study of ORV immunogenicity in India and Malawi. We then analyse the functional capacity of the developing microbiome in these cohorts. Microbiome composition differed significantly between countries, although functional capacity was more similar than taxonomic composition. Our results confirm previously reported findings that the developing microbiome is more diverse in taxonomic composition in ORV non-seroconverters compared with seroconverters, and we additionally demonstrate a similar pattern in functional capacity. Although taxonomic or functional feature abundances are poor predictors of ORV response, we show that skews in the direction of associations within these microbiome data can be used to identify consistent markers of ORV response across LMIC infant cohorts. We also highlight the systemic under-representation of reference genes from LMICs that limit functional annotation in our study (7% and 13% annotation at pathway and enzyme commission level, respectively). Overall, higher microbiome diversity in early life may act as marker for impaired ORV response in India and Malawi, whilst a holistic perspective of functional capacity may be hidden in the "dark matter" of the microbiome.

Identifiants

pubmed: 37980461
doi: 10.1186/s12866-023-03098-z
pii: 10.1186/s12866-023-03098-z
pmc: PMC10656894
doi:

Substances chimiques

Rotavirus Vaccines 0
Vaccines, Attenuated 0
Antibodies, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

354

Subventions

Organisme : Medical Research Council
ID : MR/N006259/1
Pays : United Kingdom

Informations de copyright

© 2023. The Author(s).

Références

N Engl J Med. 2010 Jan 28;362(4):289-98
pubmed: 20107214
Genome Med. 2021 Aug 27;13(1):134
pubmed: 34446072
Elife. 2021 May 04;10:
pubmed: 33944776
Vaccine. 2021 Sep 7;39(38):5391-5400
pubmed: 34393020
Nat Commun. 2021 Dec 15;12(1):7288
pubmed: 34911947
Clin Infect Dis. 2016 May 1;62 Suppl 2:S96-S105
pubmed: 27059362
PLoS Comput Biol. 2021 Nov 16;17(11):e1009442
pubmed: 34784344
EBioMedicine. 2021 Jun;68:103421
pubmed: 34139432
Science. 2014 Jun 20;344(6190):1346-8
pubmed: 24948725
mBio. 2021 Jan 12;12(1):
pubmed: 33436437
BMJ. 2018 Jun 13;361:k2179
pubmed: 29899036
PLoS Biol. 2022 Feb 15;20(2):e3001536
pubmed: 35167588
J Infect Dis. 2019 Apr 8;219(8):1178-1186
pubmed: 30247561
JAMA Pediatr. 2018 Oct 1;172(10):958-965
pubmed: 30105384
Hum Vaccin Immunother. 2021 Jun 3;17(6):1787-1802
pubmed: 33327868
Genome Biol. 2019 Nov 28;20(1):257
pubmed: 31779668
Cell Host Microbe. 2018 Aug 8;24(2):197-207.e4
pubmed: 30092197
Vaccine. 2018 Jan 4;36(2):264-272
pubmed: 29217369
Microbiome. 2018 Sep 15;6(1):158
pubmed: 30219103
Curr Opin Microbiol. 2018 Aug;44:34-40
pubmed: 30036705
BMJ Open. 2017 Mar 29;7(3):e016577
pubmed: 28360258
Nat Biotechnol. 2021 Jan;39(1):105-114
pubmed: 32690973
J Infect Dis. 2017 Jan 1;215(1):34-41
pubmed: 27803175

Auteurs

Edward Cunningham-Oakes (E)

Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK. Edward.Cunningham-Oakes@liverpool.ac.uk.
NIHR Health Protection Research Unit in Gastrointestinal Infections, Liverpool, UK. Edward.Cunningham-Oakes@liverpool.ac.uk.

Christina Bronowski (C)

Department of Clinical Infection, Microbiology and Immunology, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.

End Chinyama (E)

Virology Research Group, Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, 312225, Malawi.

Khuzwayo C Jere (KC)

NIHR Health Protection Research Unit in Gastrointestinal Infections, Liverpool, UK.
Department of Clinical Infection, Microbiology and Immunology, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.
Virology Research Group, Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, 312225, Malawi.
Department of Medical Laboratory Sciences, School of Life Sciences and Allied Health Professions, Kamuza University of Health Sciences, Blantyre, 312225, Malawi.

Kulandaipalayam Natarajan C Sindhu (KNC)

Wellcome Trust Research Laboratory, Division of Gastrointestinal Sciences, Christian Medical College, Vellore, Tamil Nadu, India.

Gagandeep Kang (G)

Wellcome Trust Research Laboratory, Division of Gastrointestinal Sciences, Christian Medical College, Vellore, Tamil Nadu, India.

Miren Iturriza-Gómara (M)

Department of Clinical Infection, Microbiology and Immunology, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.
Centre for Vaccine Innovation and Access, Program for Appropriate Technology in Health (PATH), 1218, Geneva, Switzerland.

Alistair C Darby (AC)

Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.

Edward P K Parker (EPK)

The Vaccine Centre, Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH